Differentiation between Oligodendroglioma Genotypes Using Dynamic Susceptibility Contrast Perfusion-Weighted Imaging and Proton MR Spectroscopy

Glutamate and the biology of gliomas

(2010) John de Groot et al.   GLIA

Proton Magnetic Resonance Spectroscopy in Differentiating Glioblastomas From Primary Cerebral Lymphomas and Brain Metastases

(2010) Sanjeev Chawla et al.   JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY

Dynamic susceptibility contrast perfusion weighted imaging in grading of nonenhancing astrocytomas

(2010) Naomi Morita et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Favorable long-term outcome of low-grade oligodendrogliomas irrespective of 1p/19q status when treated without radiotherapy

(2010) Yasuo Iwadate et al.   JOURNAL OF NEURO-ONCOLOGY

Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status

(2009) Gurpreet S. Kapoor et al.   JOURNAL OF NEURO-ONCOLOGY

Role of Proton Magnetic Resonance Spectroscopy in Differentiating Oligodendrogliomas from Astrocytomas

(2009) Sanjeev Chawla et al.   JOURNAL OF NEUROIMAGING

Oligodendrogliomas: Molecular Biology and Treatment

(2009) J. E. C. Bromberg et al.   ONCOLOGIST

Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas

(2008) Fabio M. Iwamoto et al.   JOURNAL OF NEURO-ONCOLOGY

Two distinct tumor phenotypes isolated from glioblastomas show different MRS characteristics

(2008) Frits Thorsen et al.   NMR IN BIOMEDICINE

Role of perfusion-weighted imaging at 3 Tesla in the assessment of malignancy of cerebral gliomas

(2008) A. Di Costanzo et al.   Radiologia Medica